Table 1 Baseline demographic and clinical characteristics
From: Evaluation of an electronic warfarin nomogram for anticoagulation of hemodialysis patients
Pre-period n = 67 | Post-period n = 55 | |
|---|---|---|
Age, mean (SD) | 69.8 (12.8) | 69.4 (14.0) |
Male (%) | 46 (68.7) | 34 (61.8) |
Diabetes (%) | 34 (50.8) | 33 (60.0) |
Cause of end stage renal disease (%) | ||
Diabetes Mellitus | 24 (35.8) | 23 (41.8) |
Vascular | 17 (25.4) | 15 (27.3) |
Glomerulonephritis | 9 (13.4) | 3 (5.5) |
Other | 9 (13.4) | 8 (11.9) |
Unknown | 8 (11.9) | 9 (16.4) |
Indication for anticoagulation (%) | ||
Thromboembolic disease | 18 (26.9) | 18 (32.7) |
Cerebrovascular disease | 1 (1.5) | 1 (1.8) |
Atrial fibrillation | 31 (46.3) | 23 (41.8) |
Vascular access patency | 4 (6.0) | 2 (3.6) |
Prosthetic valve | 3 (4.5) | 3 (5.5) |
Unspecified or unknown | 10 (14.9) | 8 (14.6) |
Range INR (%) | ||
1.5 to 2.5 | 14 (20.9) | 9 (16.4) |
2.0 to 3.0 | 51 (76.1) | 43 (78.2) |
2.5 to 3.5 | 2 (3.0) | 3 (5.5) |
Prior bleed | 11 (16.4) | 11 (20.0) |
Prior thromboembolic event | 13 (19.4) | 9 (16.4) |
Known hereditary thrombotic disease | 1 (1.5) | 1 (1.8) |
Use of Plavix | 0 (0.0) | 0 (0.0) |
Use of NSAIDs or ASA | 1 (1.5) | 1 (1.8) |
History of cancer | 10 (14.9) | 5 (9.1) |